Study proves benefit of green tea for leukemia sufferers
By Rachel Stockton, and edited by Heather Kelley
There may be hope for chronic leukemia sufferers: a compound found in a particular
green tea extract
reduces cancer cells in the most common form of the disease, chronic lymphocytic
leukemia (CLL).
The study is authored by Tait Shanafeit of the Mayo Clinic and is
being published in the Journal of Clinical Oncology. High doses of the compound epigallocatechin
gallate (EGCG) can be tolerated. The greatest benefit is to those in the early stages
of CLL: the condition is stabilized by the chemical. It is expected to work well
in tandem with other treatments. In addition, those who were studied showed a 50%
reduction in lymph node size.
Prior to this report, the chemical showed promise in
the lab; it killed cancer cells in the tissue of lab rats and of humans. This study
is the first that provides evidentiary documentation chronicling its success among
actual leukemia patients.
While green tea promises everything from protecting against
heart attack and stroke to curing all forms of cancer known to the modern world,
there has been very little clinical evidence to back up the claims.
The Pharmacology
Unit, Faculty of Medical Sciences, The University of West Indies, St. Augustine,
Trinidad and Tobago reviewed much clinical evidence earlier in the year in an effort
to either verify or disprove that green tea does all that some claim it can do. At
the end of the analysis, the researchers reported that the results of various observational
studies have been inconclusive with regards to green tea and the prevention of certain
cancers. However, they went on to say that “there are trends towards prevention in
breast and prostate cancers.”
Following the publication of the Mayo study, they will
be able to add CLL to their green tea prevention trend list.